NCT00148252终止4 期
Lowering Total Immunosuppressive Load in Renal Transplant Recipients More Than 12 Months Posttransplant - Randomised Withdrawal of Mycophenolate Mofetil (CellCept®) or Cyclosporine A (Sandimmun Neoral®)
University of Oslo School of Pharmacy18 个研究点 分布在 1 个国家目标入组 298 人开始时间: 2003年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 终止
- 发起方
- 入组人数
- 298
- 试验地点
- 18
- 主要终点
- The primary efficacy endpoint is the absolute change in renal function from inclusion to 12 months post drug withdrawal, evaluated as GFR estimated from Nankivell's formula B and normalised for 1.73 m2 body-surface.
研究概览
简要总结
To compare the change in renal function between CsA or MMF withdrawal from before to 12 months after drug withdrawal in renal transplant recipients on triple immunosuppressive therapy
详细描述
To compare the change in renal function between CsA or MMF withdrawal from before to 12 months after drug withdrawal in renal transplant recipients on triple immunosuppressive therapy.
Secondly to examine safety following withdrawal of CsA or MMF, respectively, by the following parameters:
- Biopsy verified acute rejection episodes, time to first rejection and number of steroid resistant rejection episodes within 12 months.
- Hematology (Hb, WBC, platelets) abnormalities within 12 months.
- Graft and patient survival at 12 months and 5 years. Absolute difference in renal function between withdrawal groups at 12 months. Three monthly changes in renal function from drug withdrawal to 12 months. Change in dyslipidemia frequency from drug withdrawal to 12 months. Change in hypertension frequency from drug withdrawal to 12 months. Change in glucose tolerance from drug withdrawal to 12 months. Cumulative incidence of clinical infections resulting in hospitalization within 12 months.
Sub protocols will also examine the following aspects:
Cardiovascular: Homocysteine. Lipid peroxidation. Microvascular function and vasoactive parameters Quality of life (QoL): ESRD SCL-TM, SF-36 (short version) and EQ-5D (GI-checklist extended) questionnaires will be used.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Patients of either gender above 18 years of age at time of randomisation.
- •More than twelve months posttransplant.
- •Treated with an immunosuppressive protocol consisting of CsA, MMF and steroid from the time of discharge from the transplant clinic (e.g. 3 months posttransplant).
- •4. Kidney (only) transplant recipients with stable renal function (S-creatinine < 300 umol/L and an average increase in S-creatinine < 20% the last 6 months prior to inclusion) and without treated clinically and/or biopsy proven acute rejection episodes the last 6 months prior to inclusion.
- •5. No previous steroid resistant acute rejections (e.g. treated with ATG/OKT3).
- •Not more than two steroid sensitive acute rejections posttransplant.
- •Signed informed consent.
排除标准
- •PRA positivity > 20%.
- •Concomitant therapy with other investigational drugs or prohibited medication specified in the protocol.
- •3. Life expectancy less than one year.
- •Acute illness or acute fungal, bacterial or viral infection at screening.
- •Unable and/or unlikely to follow the study protocol.
结局指标
主要结局
The primary efficacy endpoint is the absolute change in renal function from inclusion to 12 months post drug withdrawal, evaluated as GFR estimated from Nankivell's formula B and normalised for 1.73 m2 body-surface.
次要结局
- Graft and patient survival at 12 months and 5 years posttransplant.
- Proportion of patients with biopsy-proven acute rejection or acute rejection (biopsy proven + presumptive) episodes within 12 months.
- Incidence of HB, WBC, platelet abnormal values requiring clinical intervention within 12 months.
- Incidence of need for additional immunosuppressive therapy at 12 months.
- Absolute difference in renal function between treatment groups at 12 months, evaluated by Nankivell's formula (B).
- Renal function (Nankivell's formula B) development over time (3 monthly) between treatment groups within 12 months.
- Change in dyslipidemia frequency from drug withdrawal to 12 months.
- Change in hypertension frequency from drug withdrawal to 12 months.
- Change in glucose tolerance from drug withdrawal to 12 months.
- Cumulative incidence of clinical infections resulting in hospitalization within 12 months.
研究者
研究点 (18)
Loading locations...
相似试验
已完成
3 期
12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant PatientsKidney TransplantationRenal TransplantationNCT01843348Novartis Pharmaceuticals612
招募中
4 期
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.Kidney TransplantationMycophenolate MofetilNCT06568549Mayo Clinic350
已完成
不适用
Immunosuppressive Regimen on Changes in Renal Function and Transplant Rejection Rate in Patients With Lung TransplantChronic Kidney DiseasesLung Transplant ComplicationsNCT03657004University of Giessen145
已完成
3 期
Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose RegimenKidney TransplantationNCT00514514Novartis Pharmaceuticals802
招募中
不适用
ADOLESCE-NT Studie.NL-OMON27975Erasmus MC125